Evolus (EOLS) Other Non-Current Assets (2017 - 2026)
Evolus (EOLS) posted Other Non-Current Assets of $1.6 million for Q1 2026, up 37.45% on a QoQ basis from $1.2 million in Q4 2025, and up 83.11% year-over-year from $900000.0 in Q1 2025.
Evolus (EOLS) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Evolus' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- Quarterly Other Non-Current Assets rose 83.11% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 83.11% YoY) and the FY2025 annual result came in at $1.2 million, up 39.74% from the prior year.
- Other Non-Current Assets was $1.6 million for Q1 2026 at Evolus, up from $1.2 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.8 million in Q4 2022 and bottomed at $222000.0 in Q3 2023.
- A 5-year average of $1.4 million and a median of $1.2 million in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 1005.83% — and 2023, when it tumbled 91.25%.
- Evolus' Other Non-Current Assets stood at $2.8 million in 2022, then slumped by 85.46% to $409000.0 in 2023, then jumped by 109.78% to $858000.0 in 2024, then surged by 39.74% to $1.2 million in 2025, then surged by 37.45% to $1.6 million in 2026.
- Business Quant data shows EOLS's Other Non-Current Assets at $1.6 million in Q1 2026, $1.2 million in Q4 2025, and $1.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | 1.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.65 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.58 Mn |
| Jun 30, 2025 | 1.80 Mn |
| Mar 31, 2025 | 900,000.00 |
| Dec 31, 2024 | 858,000.00 |
| Sep 30, 2024 | 858,000.00 |
| Jun 30, 2024 | 409,000.00 |
| Mar 31, 2024 | 409,000.00 |
| Dec 31, 2023 | 409,000.00 |
| Sep 30, 2023 | 222,000.00 |
| Jun 30, 2023 | 223,000.00 |
| Mar 31, 2023 | 2.68 Mn |
| Dec 31, 2022 | 2.81 Mn |
| Sep 30, 2022 | 2.43 Mn |
| Jun 30, 2022 | 2.55 Mn |
| Mar 31, 2022 | 2.65 Mn |
| Dec 31, 2021 | 2.76 Mn |
| Sep 30, 2021 | 240,000.00 |
| Jun 30, 2021 | 240,000.00 |